Barclays’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-535,506
| Closed | -$45.5M | – | 5289 |
|
|
2020
Q3 | $45.5M | Buy |
535,506
+255,546
| +91% | +$12.9M | 0.03% | 424 |
|
|
2020
Q2 | $9.92M | Sell |
279,960
-46,320
| -14% | -$1.35M | 0.01% | 968 |
|
|
2020
Q1 | $4.4M | Sell |
326,280
-86,716
| -21% | -$1.46M | ﹤0.01% | 1576 |
|
|
2019
Q4 | $8.74M | Buy |
412,996
+157,743
| +62% | +$2.78M | ﹤0.01% | 1505 |
|
|
2019
Q3 | $3.38M | Buy |
255,253
+116,027
| +83% | +$1.71M | ﹤0.01% | 2255 |
|
|
2019
Q2 | $1.93M | Buy |
139,226
+38,089
| +38% | +$573K | ﹤0.01% | 2960 |
|
|
2019
Q1 | $1.94M | Sell |
101,137
-68,376
| -40% | -$1.1M | ﹤0.01% | 2603 |
|
|
2018
Q4 | $2.42M | Sell |
169,513
-286,692
| -63% | -$5.69M | ﹤0.01% | 2223 |
|
|
2018
Q3 | $9.5M | Buy |
456,205
+121,519
| +36% | +$2.88M | 0.01% | 1295 |
|
|
2018
Q2 | $7.92M | Buy |
334,686
+6,459
| +2% | +$130K | 0.01% | 1391 |
|
|
2018
Q1 | $4.79M | Buy |
328,227
+66,491
| +25% | +$1.09M | ﹤0.01% | 1669 |
|
|
2017
Q4 | $4.23M | Buy |
261,736
+255,516
| +4,108% | +$3.02M | ﹤0.01% | 1796 |
|
|
2017
Q3 | $87K | Sell |
6,220
-67,925
| -92% | -$677K | ﹤0.01% | 5021 |
|
|
2017
Q2 | $655K | Sell |
74,145
-35,077
| -32% | -$246K | ﹤0.01% | 3256 |
|
|
2017
Q1 | $706K | Sell |
109,222
-19,855
| -15% | -$101K | ﹤0.01% | 3067 |
|
|
2016
Q4 | $474K | Buy |
129,077
+113,861
| +748% | +$337K | ﹤0.01% | 3413 |
|
|
2016
Q3 | $50K | Buy |
15,216
+1,325
| +10% | +$3.71K | ﹤0.01% | 4980 |
|
|
2016
Q2 | $32K | Sell |
13,891
-297,025
| -96% | -$993K | ﹤0.01% | 5080 |
|
|
2016
Q1 | $622K | Buy |
310,916
+147,790
| +91% | +$332K | ﹤0.01% | 2951 |
|
|
2015
Q4 | $489K | Buy |
163,126
+134,095
| +462% | +$374K | ﹤0.01% | 3241 |
|
|
2015
Q3 | $30K | Sell |
29,031
-120,459
| -81% | -$307K | ﹤0.01% | 5289 |
|
|
2015
Q2 | $598K | Buy |
149,490
+16,485
| +12% | +$67.4K | ﹤0.01% | 3326 |
|
|
2015
Q1 | $399K | Buy |
133,005
+22,903
| +21% | +$99.6K | ﹤0.01% | 3802 |
|
|
2014
Q4 | $440K | Buy |
110,102
+58,427
| +113% | +$231K | ﹤0.01% | 3989 |
|
|
2014
Q3 | $155K | Sell |
51,675
-1,148
| -2% | -$3.88K | ﹤0.01% | 4962 |
|
|
2014
Q2 | $158K | Sell |
52,823
-40,133
| -43% | -$147K | ﹤0.01% | 5038 |
|
|
2014
Q1 | $373K | Buy |
92,956
+58,803
| +172% | +$292K | ﹤0.01% | 4196 |
|
|
2013
Q4 | $137K | Buy |
34,153
+27,646
| +425% | +$123K | ﹤0.01% | 5360 |
|
|
2013
Q3 | $39K | Buy |
6,507
+432
| +7% | +$2.49K | ﹤0.01% | 6195 |
|
|
2013
Q2 | $33K | Buy |
+6,075
| New | +$20K | ﹤0.01% | 6575 |
|
Barclays's IMMU Position: Q4 2020 in Review
Barclays sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 535,506 shares — an estimated $45.5M sold.
Barclays first reported a position in IMMU in Q2 2013 and held it in 30 quarters. The position peaked at $45.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Barclays reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Barclays sold 535,506 Immunomedics Inc shares in Q4 2020, an estimated $45.5M.
- Barclays first reported a position in Immunomedics Inc in Q2 2013 and held it in 30 quarters.
- Barclays's Immunomedics Inc position peaked at $45.5M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.